| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2006-05-18 08:50:34 UTC |
|---|
| Update Date | 2022-03-07 02:49:25 UTC |
|---|
| HMDB ID | HMDB0005034 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Topiramate |
|---|
| Description | Topiramate is an anticonvulsant drug used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also Food and Drug Administration (FDA) approved, and now most frequently prescribed for, the prevention of migraines. It has been used by psychiatrists to treat bipolar disorder, although it is not FDA approved for this purpose and such use is somewhat controversial. This drug has been investigated for use in treatment of obesity, especially to aid in the reduction of binge eating, and also as a possible treatment for alcoholism. However, these uses are not actively promoted by the manufacturer, and like its use for bipolar disorder, are 'off-label' uses. The drug is also used in clinical trials to treat Post Traumatic Stress Disorder. A pilot study suggests that Topiramate is possibly effective against infantile spasm; Chemically, topiramate is a sulfamate-substituted monosaccharide, related to fructose, a rather unusual chemical structure for an anticonvulsant. Topiramate is quickly absorbed after oral use. Most of the drug (70%) is excreted in the urine as unchanged drug. The remainder is extensively metabolized by hydroxylation, hydrolysis, and glucuronidation. Six metabolites have been identified in humans, none of which constitutes more than 5% of an administered dose. Topiramate enhances GABA-activated chloride channels. In addition, topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. There is evidence that topiramate has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particularly subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages. Topiramate inhibits maximal electroshock and pentylenetetrazol-induced seizures as well as partial and secondarily generalized tonic-clonic seizures in the kindling model, findings predictive of a broad spectrum of antiseizure activities clinically; Johnson. It is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also Food and Drug Administration (FDA) approved for, and now most frequently prescribed for, the prevention of migraines. It has been used by psychiatrists to treat bipolar disorder, although it is not FDA approved for this purpose and such use is somewhat controversial. This drug has been investigated for use in treatment of obesity, especially to aid in the reduction of binge eating, and also as a possible treatment for alcoholism. However, these uses are not actively promoted by the manufacturer, and like its use for bipolar disorder, are 'off-label' uses. The drug is also used in clinical trials to treat Post Traumatic Stress Disorder. A pilot study suggests that Topiramate is possibly effective against infantile spasm. In May 2006 the U.S. National Institutes of Health web site clinicaltrials.gov listed several studies sponsored by Ortho-McNeil which propose to examine the use of topiramate on migraine, cluster, and severe headaches within various demographics; Topiramate (brand name: Topamax) is an anticonvulsant drug produced by Ortho-McNeil, a division of Johnson & Topiramate (brand name: Topamax) is an anticonvulsant drug produced by Ortho-McNeil, a division of Johnson & Johnson. It is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also Food and Drug Administration (FDA) approved for, and now most frequently prescribed for, the prevention of migraines. It has been used by psychiatrists to treat bipolar disorder, although it is not FDA approved for this purpose and such use is somewhat controversial. This drug has been investigated for use in treatment of obesity, especially to aid in the reduction of binge eating, and also as a possible treatment for alcoholism. However, these uses are not actively promoted by the manufacturer, and like its use for bipolar disorder, are 'off-label' uses. The drug is also used in clinical trials to treat Post Traumatic Stress Disorder. A pilot study suggests that Topiramate is possibly effective against infantile spasm. In May 2006 the U.S. National Institutes of Health web site clinicaltrials.gov listed several studies sponsored by Ortho-McNeil which propose to examine the use of topiramate on migraine, cluster, and severe headaches within various demographics. |
|---|
| Structure | [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2 InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate | ChEBI | | 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate | ChEBI | | MCN-4853 | ChEBI | | RWJ-17021 | ChEBI | | Tipiramate | ChEBI | | Tipiramato | ChEBI | | Topamax | ChEBI | | Topiramato | ChEBI | | Topiramatum | ChEBI | | TPM | ChEBI | | Trokendi XR | Kegg | | 2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamate | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamic acid | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamate | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamic acid | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamic acid | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamate | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamic acid | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamic acid | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamate | Generator | | 2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamic acid | Generator | | 2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamate | Generator | | 2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamic acid | Generator | | 2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamate | Generator | | 2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamic acid | Generator | | 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamic acid | Generator | | 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamate | Generator | | 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamic acid | Generator | | 2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamate | Generator | | 2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamic acid | Generator | | 2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamate | Generator | | 2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamic acid | Generator | | Tipiramic acid | Generator | | Topiramic acid | Generator | | Epitomax | HMDB | | Topamax sprinkle | HMDB | | Topomax | HMDB | | 2,3-4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate | HMDB |
|
|---|
| Chemical Formula | C12H21NO8S |
|---|
| Average Molecular Weight | 339.362 |
|---|
| Monoisotopic Molecular Weight | 339.098787343 |
|---|
| IUPAC Name | [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0²,⁶]dodecan-6-yl]methyl sulfamate |
|---|
| Traditional Name | topiramate |
|---|
| CAS Registry Number | 97240-79-4 |
|---|
| SMILES | [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2 |
|---|
| InChI Identifier | InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1 |
|---|
| InChI Key | KJADKKWYZYXHBB-XBWDGYHZSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as dioxolopyrans. Dioxolopyrans are compounds containing a dioxolopyran moiety, which consists of a dioxole ring fused to a pyran ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Dioxolopyrans |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Dioxolopyrans |
|---|
| Alternative Parents | |
|---|
| Substituents | - Dioxolopyran
- Ketal
- Oxane
- Monosaccharide
- Organic sulfuric acid or derivatives
- Meta-dioxolane
- Oxacycle
- Acetal
- Organic nitrogen compound
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Aliphatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aliphatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 125 - 126 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.26 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.1876 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.66 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 25.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2283.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 303.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 146.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 165.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 92.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 642.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 381.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 70.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1022.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 418.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1628.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 394.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 339.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 252.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 216.9 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.7 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Topiramate,1TMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N[Si](C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 2305.4 | Semi standard non polar | 33892256 | | Topiramate,1TMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N[Si](C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 2477.2 | Standard non polar | 33892256 | | Topiramate,1TMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N[Si](C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 3219.1 | Standard polar | 33892256 | | Topiramate,2TMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 2370.4 | Semi standard non polar | 33892256 | | Topiramate,2TMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 2685.7 | Standard non polar | 33892256 | | Topiramate,2TMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 3161.8 | Standard polar | 33892256 | | Topiramate,1TBDMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N[Si](C)(C)C(C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 2539.6 | Semi standard non polar | 33892256 | | Topiramate,1TBDMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N[Si](C)(C)C(C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 2791.0 | Standard non polar | 33892256 | | Topiramate,1TBDMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N[Si](C)(C)C(C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 3268.3 | Standard polar | 33892256 | | Topiramate,2TBDMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 2771.3 | Semi standard non polar | 33892256 | | Topiramate,2TBDMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 3223.3 | Standard non polar | 33892256 | | Topiramate,2TBDMS,isomer #1 | CC1(C)O[C@@H]2CO[C@@]3(COS(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)OC(C)(C)O[C@H]3[C@@H]2O1 | 3257.0 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Topiramate GC-MS (Non-derivatized) - 70eV, Positive | splash10-003r-5893000000-57939ef42b569234ad29 | 2017-08-28 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Topiramate GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate LC-ESI-qTof , Positive-QTOF | splash10-03di-0239000000-994a7b97e101c455a792 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate LC-ESI-qTof , Positive-QTOF | splash10-01x0-1970000000-f0e80f5cc5d6fc2b6d38 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate Linear Ion Trap , negative-QTOF | splash10-01q9-2960000000-a11a150bcada5055d2e9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate Linear Ion Trap , positive-QTOF | splash10-014i-0090000000-c1fa3d6ff15890fc1418 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate Linear Ion Trap , positive-QTOF | splash10-00di-0059000000-a6337903cab01edce60e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate , positive-QTOF | splash10-03di-0239000000-994a7b97e101c455a792 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate , positive-QTOF | splash10-01x0-1970000000-f0e80f5cc5d6fc2b6d38 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate 60V, Negative-QTOF | splash10-004i-9000000000-a8df5a6ea132d69b9489 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate 45V, Negative-QTOF | splash10-004i-9000000000-f76d8f2283f18dfa20be | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate 75V, Negative-QTOF | splash10-004i-9000000000-316320612e65b9d317cb | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate 90V, Negative-QTOF | splash10-004i-9000000000-63d6b2cbde40b2bcd639 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate 30V, Negative-QTOF | splash10-004i-9003000000-0b8ee634478a6f2f0eee | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate 15V, Negative-QTOF | splash10-000i-0009000000-086098dbff51e692c04f | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate 35V, Positive-QTOF | splash10-0c0r-9850000000-ae199550ba647589f088 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Topiramate 35V, Negative-QTOF | splash10-004i-9000000000-eab734dd0ed786cbba6d | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 10V, Positive-QTOF | splash10-0006-1029000000-37869fd8dcd3ec0f4cc1 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 20V, Positive-QTOF | splash10-01po-4295000000-7cdbdca2d1d67b21879d | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 40V, Positive-QTOF | splash10-03fr-9810000000-9b5c3fb12c27e09cf450 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 10V, Negative-QTOF | splash10-002r-4239000000-e56f7b1fecd3064e8783 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 20V, Negative-QTOF | splash10-004j-9164000000-892445ea4dcd3bf9420d | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 40V, Negative-QTOF | splash10-004i-9100000000-7c64b90d0daae2c6e5b8 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 10V, Positive-QTOF | splash10-0006-0009000000-9a74f9cc10019d27995c | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 20V, Positive-QTOF | splash10-0006-0149000000-093e852afab8097cfa0f | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 40V, Positive-QTOF | splash10-03dm-8790000000-0a33128bbe614c27cdf7 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Topiramate 10V, Negative-QTOF | splash10-000i-0019000000-345311bd602424b95a49 | 2021-09-24 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
- Petroff OA, Hyder F, Mattson RH, Rothman DL: Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology. 1999 Feb;52(3):473-8. [PubMed:10025774 ]
|
|---|